GlaxoSmithKline PLC (GSK.LN) Monday announced positive results for its malaria treatment tafenoquine in Phase III testing.
The drug giant said a single dose the treatment, used to prevent relapses of Plasmodium vivax malaria, reduced the risk of relapse in patients significantly more than a placebo when given alongside a 3-day blood-stage chloroquine treatment.
Continue Reading Below
Shares at 1113 GMT, down 4 pence, or 0.2%, at 1,695 pence valuing the company at GBP83.3 billion.
-Write to Rory Gallivan at firstname.lastname@example.org; Twitter: @RoryGallivan
(END) Dow Jones Newswires
June 12, 2017 07:29 ET (11:29 GMT)